Thursday, February 23, 2012
Technology Networks
Technology Networks
| but-home | but-products | but-resources | but-jobs | but-events | but-posters | but-videos | but-webcasts | but-forums | but-end |
 |  |
|
|
 | Hospital Integrated Biobanking and Prospective Cancer Biobanking (U-Can) Anna Beskow, Director of Uppsala Biobank, speaking at World Biobanking Summit 2011. |
 | Use of Mesenchymal Stem Cells for Therapies in the Lung Mauricio Rojas, Assistant Professor, University of Pittsburgh speaking at Stem Cells World Congress 2011 |
3D Cell Culture Trends
HTStec
This market report summarizes the results of HTStec’s second industry-wide global web-based benchmarking survey on three dimensional (3D) cell culture carried out in October 2011.
Preclinical Development of Monoclonal Antibodies and Related Biologicals: Emerging technologies and new therapeutic candidates
Business Insights
This report explains what monoclonal antibodies are, and why large pharmaceutical companies are investing so heavily both in developing such drugs internally and acquiring monoclonal antibody candidates from others. More than 80 popular and emerging technologies are named, explained and illustrated with original full-color diagrams.
Global Biosimilars (Follow-on biologics) Market: An Analysis
Koncept Analytics
The report covers the overview, market size and segmentation of the biosimilars market. The various drivers and the challenges faced by the market are also discussed in detail. The competitive aspect of the market is also highlighted and the key players are profiled with their strategies for this market.
Cell-Based Assays For Biologics Trends 2011
HTStec
This market report summarizes the results of HTStec’s industry-wide global web-based benchmarking survey on cell-based assays for biologics carried out in July 2011.
Umbilical Cord Blood Banking Market Trends 2011
Select Biosciences Ltd
This report focuses upon cord blood banking and provided quantitative market analysis of the space as it relates to the growth of the field, utilization trends of cord blood for different diseases in different countries of the world.
Innovations in Combating Infectious Diseases: Opportunities in therapeutics and diagnostics through application of proteomics, genomics, nanotechnology, and novel sources of lead generation
Business Insights
This report makes a detailed and comprehensive analysis of the cutting edge of research aiming to reveal how bacteria, viruses, fungi, and prions infect and affect their hosts. It also assesses the new technologies and techniques that are being used to design and develop the anti-infective drugs and diagnostic methods of the 21st century.
Biostorage Trends 2010
HTStec
This market report summarizes the results of HTStec’s global web-based benchmarking survey on biological sample storage carried out in July 2010. The objectives of the study were to comprehensively document current practices and preferences in biological sample storage and to understand future user requirements.
Cancer Vaccines & Circulating Tumor Cells (CTCs) 2011 Report
Select Biosciences Ltd
This market report from Select Biosciences presents a comprehensive industry analysis of the cancer vaccines space as well as that of the emerging circulating tumor cells (CTCs) space. These two areas are evolving and expanding driven by the greater emphasis on personalized medicine especially in the cancer/oncology space.
Biosimilars and Biobetters: Positioning for a New Market
Select Biosciences Ltd
As regulatory frameworks for biosimilars development begin to take shape worldwide, there are growing opportunities for generics companies to enter the biologics market, a segment which is uniquely driven by unmet needs, commands premium prices, and continues to outperform the global pharma market.
Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies
GBI Research
GBI Research's report, “Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies”, provides the key data and analyzes the major challenges and drivers for the biomanufacturing industry. The report also analyzes the strengths, weaknesses of and opportunities for the stakeholders in the manufacturing of biologics.
HTStec
This market report summarizes the results of HTStec’s second industry-wide global web-based benchmarking survey on three dimensional (3D) cell culture carried out in October 2011.
Preclinical Development of Monoclonal Antibodies and Related Biologicals: Emerging technologies and new therapeutic candidates
Business Insights
This report explains what monoclonal antibodies are, and why large pharmaceutical companies are investing so heavily both in developing such drugs internally and acquiring monoclonal antibody candidates from others. More than 80 popular and emerging technologies are named, explained and illustrated with original full-color diagrams.
Global Biosimilars (Follow-on biologics) Market: An Analysis
Koncept Analytics
The report covers the overview, market size and segmentation of the biosimilars market. The various drivers and the challenges faced by the market are also discussed in detail. The competitive aspect of the market is also highlighted and the key players are profiled with their strategies for this market.
Cell-Based Assays For Biologics Trends 2011
HTStec
This market report summarizes the results of HTStec’s industry-wide global web-based benchmarking survey on cell-based assays for biologics carried out in July 2011.
Umbilical Cord Blood Banking Market Trends 2011
Select Biosciences Ltd
This report focuses upon cord blood banking and provided quantitative market analysis of the space as it relates to the growth of the field, utilization trends of cord blood for different diseases in different countries of the world.
Innovations in Combating Infectious Diseases: Opportunities in therapeutics and diagnostics through application of proteomics, genomics, nanotechnology, and novel sources of lead generation
Business Insights
This report makes a detailed and comprehensive analysis of the cutting edge of research aiming to reveal how bacteria, viruses, fungi, and prions infect and affect their hosts. It also assesses the new technologies and techniques that are being used to design and develop the anti-infective drugs and diagnostic methods of the 21st century.
Biostorage Trends 2010
HTStec
This market report summarizes the results of HTStec’s global web-based benchmarking survey on biological sample storage carried out in July 2010. The objectives of the study were to comprehensively document current practices and preferences in biological sample storage and to understand future user requirements.
Cancer Vaccines & Circulating Tumor Cells (CTCs) 2011 Report
Select Biosciences Ltd
This market report from Select Biosciences presents a comprehensive industry analysis of the cancer vaccines space as well as that of the emerging circulating tumor cells (CTCs) space. These two areas are evolving and expanding driven by the greater emphasis on personalized medicine especially in the cancer/oncology space.
Biosimilars and Biobetters: Positioning for a New Market
Select Biosciences Ltd
As regulatory frameworks for biosimilars development begin to take shape worldwide, there are growing opportunities for generics companies to enter the biologics market, a segment which is uniquely driven by unmet needs, commands premium prices, and continues to outperform the global pharma market.
Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies
GBI Research
GBI Research's report, “Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies”, provides the key data and analyzes the major challenges and drivers for the biomanufacturing industry. The report also analyzes the strengths, weaknesses of and opportunities for the stakeholders in the manufacturing of biologics.
FDA Issues Draft Guidance on Biosimilar Product Development
The three draft guidance documents on biosimilar product development are to assist industry in developing such products in the United States.
Compugen Cancer Target Results Demonstrate Significant Potential for Cancer Immunotherapy
Findings support CGEN-15001T's potential as a powerful drug target for cancer immunotherapy.
NIH-funded HIV Clinical Research Sites to Join Pediatric Tuberculosis Vaccine Study
Several U.S. government-funded HIV/AIDS clinical research sites in Africa will join other collaborators in an ongoing clinical trial testing an investigational tuberculosis vaccine in infants at risk for TB infection.
Auxilium Pharmaceuticals, Inc. Announces First Patients Dosed in XIAFLEX® Phase Ib Cellulite Study
The objectives of the study are to assess the safety, effectiveness, and pharmacokinetics of XIAFLEX for the treatment of EFP.
Neonatal Respiratory Distress Syndrome Treatment Comparison Shows Lower Mortality Rates
New analysis published in eFirst pages of Pediatrics website also shows reduced need for redosing when using CUROSURF Intratracheal Suspension.
VentiRx Pharmaceuticals Publishes Preclinical Data of Novel TLR8 Agonist
The data collected on VTX-2337 supports its potential as an immunotherapeutic approach in cancer. The preclinical data published in Clinical Cancer Research also underscores important differences between TLRs in human immune responses.
La Jolla Pharmaceutical Company Acquires GCS-100
The first-in-class clinical-stage compound inhibits Galectin-3, implicated in cancer and chronic organ failure.
Trimel Pharmaceuticals Corporation Completes Patient Enrollment of CompleoTRT Phase III Safety Cohort
The Phase III study represents the final stage of product development prior to Trimel anticipated submission of a New Drug Application (NDA) to the FDA for marketing approval in the United States.
Celldex Therapeutics Announces Initiation of Phase 1 Clinical Trial of CDX-301
The company announced that dosing was initiated in a Phase 1 study of its hematopoietic growth factor, CDX-301, in healthy subjects. The study is being conducted in collaboration with Rockefeller University.
Spherix Announces Successful Completion of Important Toxicology Study of SPX-106
The company reported the successful completion of its 28-day rat toxicology. Results demonstrated an ample margin of safety with the dosing planned for the first-in-human study.
The three draft guidance documents on biosimilar product development are to assist industry in developing such products in the United States.
Compugen Cancer Target Results Demonstrate Significant Potential for Cancer Immunotherapy
Findings support CGEN-15001T's potential as a powerful drug target for cancer immunotherapy.
NIH-funded HIV Clinical Research Sites to Join Pediatric Tuberculosis Vaccine Study
Several U.S. government-funded HIV/AIDS clinical research sites in Africa will join other collaborators in an ongoing clinical trial testing an investigational tuberculosis vaccine in infants at risk for TB infection.
Auxilium Pharmaceuticals, Inc. Announces First Patients Dosed in XIAFLEX® Phase Ib Cellulite Study
The objectives of the study are to assess the safety, effectiveness, and pharmacokinetics of XIAFLEX for the treatment of EFP.
Neonatal Respiratory Distress Syndrome Treatment Comparison Shows Lower Mortality Rates
New analysis published in eFirst pages of Pediatrics website also shows reduced need for redosing when using CUROSURF Intratracheal Suspension.
VentiRx Pharmaceuticals Publishes Preclinical Data of Novel TLR8 Agonist
The data collected on VTX-2337 supports its potential as an immunotherapeutic approach in cancer. The preclinical data published in Clinical Cancer Research also underscores important differences between TLRs in human immune responses.
La Jolla Pharmaceutical Company Acquires GCS-100
The first-in-class clinical-stage compound inhibits Galectin-3, implicated in cancer and chronic organ failure.
Trimel Pharmaceuticals Corporation Completes Patient Enrollment of CompleoTRT Phase III Safety Cohort
The Phase III study represents the final stage of product development prior to Trimel anticipated submission of a New Drug Application (NDA) to the FDA for marketing approval in the United States.
Celldex Therapeutics Announces Initiation of Phase 1 Clinical Trial of CDX-301
The company announced that dosing was initiated in a Phase 1 study of its hematopoietic growth factor, CDX-301, in healthy subjects. The study is being conducted in collaboration with Rockefeller University.
Spherix Announces Successful Completion of Important Toxicology Study of SPX-106
The company reported the successful completion of its 28-day rat toxicology. Results demonstrated an ample margin of safety with the dosing planned for the first-in-human study.
Genticel Completed Recruitment for its Phase Ib Vaccine Trial in HPV Infected Women
Company expects the final results before the end of the second quarter 2012.
Honouring the Best Innovators, Pioneers and Leaders in Asia
The BioPharma Awards aims to acknowledge the dedication and success of industry leaders and companies globally and in Asia.
Critical Pharmaceuticals and The University of Nottingham to Develop Nano-Enabled Nasal Spray for Osteoporosis
The Technology Strategy Board and the Engineering and Physical Sciences Research Council (EPSRC) provide grant funding to support the £545,000 project.
BD Diagnostics Expands Portfolio with Automated Instrumentation Technologies
Company announced the expansion of its microbiology portfolio to include new automated instrumentation technologies that will enable the Company to offer innovative total lab automation solutions to hospitals and laboratories worldwide.
Allena Pharmaceuticals Appoints Gino Santini to Board of Directors
Former Eli Lilly and Company Senior Executive brings extensive line management, strategic planning, product and transaction expertise.
Sirona Biochem Appoints Three Chemistry Experts to Subsidiary Scientific Advisory Board
Appointment of Professor Pierre Vogel, Dr. Bernard Langlois and Dr. Eric Leclerc to the Scientific Advisory Board.
LifeLines Biobank Buys New BiOS System from Hamilton Storage Technologies
Eight million samples from three-generation study will be managed by automated system.
SeraCare Announces Definitive Agreement to be Acquired by Linden Capital Partners
Under the terms of the agreement, holders of outstanding shares of common stock of SeraCare will receive $4.00 per share, representing a 25% premium to the 30-day volume-weighted average stock price.
Quincy Bioscience Begins Recruitment for Migraine Study
Study will evaluate the effectiveness of the jellyfish calcium-binding protein apoaequorin on quality of life for migraine sufferers.
Cytomedix Expands Commitment to Regenerative Medicine with Acquisition of Aldegen
Under the terms of the transaction as described below, Cytomedix issued preferred shares valued at $16 million based on a 10-day volume-weighted average price calculated through February 2, 2012.
Company expects the final results before the end of the second quarter 2012.
Honouring the Best Innovators, Pioneers and Leaders in Asia
The BioPharma Awards aims to acknowledge the dedication and success of industry leaders and companies globally and in Asia.
Critical Pharmaceuticals and The University of Nottingham to Develop Nano-Enabled Nasal Spray for Osteoporosis
The Technology Strategy Board and the Engineering and Physical Sciences Research Council (EPSRC) provide grant funding to support the £545,000 project.
BD Diagnostics Expands Portfolio with Automated Instrumentation Technologies
Company announced the expansion of its microbiology portfolio to include new automated instrumentation technologies that will enable the Company to offer innovative total lab automation solutions to hospitals and laboratories worldwide.
Allena Pharmaceuticals Appoints Gino Santini to Board of Directors
Former Eli Lilly and Company Senior Executive brings extensive line management, strategic planning, product and transaction expertise.
Sirona Biochem Appoints Three Chemistry Experts to Subsidiary Scientific Advisory Board
Appointment of Professor Pierre Vogel, Dr. Bernard Langlois and Dr. Eric Leclerc to the Scientific Advisory Board.
LifeLines Biobank Buys New BiOS System from Hamilton Storage Technologies
Eight million samples from three-generation study will be managed by automated system.
SeraCare Announces Definitive Agreement to be Acquired by Linden Capital Partners
Under the terms of the agreement, holders of outstanding shares of common stock of SeraCare will receive $4.00 per share, representing a 25% premium to the 30-day volume-weighted average stock price.
Quincy Bioscience Begins Recruitment for Migraine Study
Study will evaluate the effectiveness of the jellyfish calcium-binding protein apoaequorin on quality of life for migraine sufferers.
Cytomedix Expands Commitment to Regenerative Medicine with Acquisition of Aldegen
Under the terms of the transaction as described below, Cytomedix issued preferred shares valued at $16 million based on a 10-day volume-weighted average price calculated through February 2, 2012.
 | ||||||||||||||||
|
Automated Solutions for Cellular Screening and Characterization of Therapeutic Antibodies for Antibody-Dependent Cellular Cytotoxicity Utility
BioTek Instruments
Since the end of the 1990’s, the pharmaceutical industry has seen an increased interest in biologics, especially in the therapeutic areas of oncology and inflammation. Here we present the automation of two assays for the characterization and selection of potent antibody drug candidates. Both assays rely on HTRF® detection. The first assay quantifies the binding affinity of antibodies to their target antigen, on live cells.
Validation of an Automated Cell-Based Bioluminescent TNFa Blocker Bioassay
BioTek Instruments
TNFa blocker biopharmaceuticals represent an important and successful class of protein drugs used in the treatment of several autoimmune diseases. Bioassays are indispensible tools in biopharmaceutical drug development and commercialization that are used to quantify biological activity and stability of drugs or drug candidates. The automation of these assays can serve to create an accurate, robust process which can allow the researcher to perform other more important functions.
Improving Cell-Mediated Cytotoxicity Assessment through the Use of an Automated Luminescent ADCC Assay
BioTek Instruments
Assays that can assess the ability of a biosimilar to act in a manner similar to the original biologic have seen increased interest. This poster describes the use of a non-radioactive luminescent chemistry to simplify the assay process and provide improved data quality.
Antigen Determination in Autoimmune Hepatitis Type1
Institute of Liver and Biliary Sciences
Objectives of this project were to exploit the database in indian setting to determine nuclear antigens as target for antinuclear antibodies (ANA) in patients of autoimmune hapatitis (AIH) type1.
Biopharmaceuticals Hiding in the Woods
University of New Brunswick
Suggestions are provided of how efficient industrial bioprocessing can be accomplished, independently of highly expensive molecular biology approaches, in order to recover natural products of medicinal value from wild plant species.
Expansion of mesenchymal stem cells from frozen UCB
StemCare A/S and Bioneer A/S
Umbilical cord blood (UCB) has recently been the focus of clinical applications. UCB contains of hematopoietic stem cells and mesenchymal stem cells (MSC). Clinical studies shows that MSC can be used in regenerative medicine hereby treatment of cardiac diseases. The aim of this project is to establish a protocol for isolation of MSCs from frozen UCB. This study demonstrated that it’s possible to expand MSC.
A Mix-and-Read Cell-Based Assay for Antibody Screening Against Epidermal Growth Factor Receptor
TTP Labtech Ltd
The conventional antibody screening assay based on antibody-antigen binding has been enzyme-linked immunosorbent assay (ELISA). While tedious and consuming, ELISA has proved sufficient for the identification of antibodies directed against secreted antigens. However, cell surface antigens (e.g. GPCRs) provide challenges for ELISA due to the shortage of soluble antigens and high variability resulting from loss of cells during wash procedures.
Facing the challenges in bio-pharmaceutical production: newly developed polymer-based ion exchange chromatography media and their application to the purification for Immunoglobulin – from egg yolk
YMC
Much attention has been given to ion exchange (IEX) media as a means to improve productivity as a result of increasing demand for higher efficiency on the downstream process. Until recently, strain optimisation for high productivity and upstream purification were the bottlenecks for most bio-processes.
Development and NDA-Level Validation of a Real-Time PCR Procedure for Detection and Quantification of Residual E.coli DNA Contamination of Biopharmaceutical Products
Aptuit, Inc.
Escherichia coli (E. coli) has been commonly used for the production of biopharmaceuticals. Among the impurities that must be monitored in biopharmaceuticals is residual host-cell DNA (HCD). This study describes the development and subsequent NDA-level validation of a real time PCR procedure developed in response to a client’s need to improve the sensitivity of detection and quantification of residual E. coli HCD in their drug product.
Gene Expression Profiling of Archived FFPE Samples
Miltenyi Biotech
According to the BBMRI (Biobanking and Biomolecular Resources Research Infrastructure) about 8,000,000 formalin-fixed paraffin-embedded (FFPE) samples derived from a multitude of different diseases have been collected in medical centers and biobanks all over Europe during the last decades.
BioTek Instruments
Since the end of the 1990’s, the pharmaceutical industry has seen an increased interest in biologics, especially in the therapeutic areas of oncology and inflammation. Here we present the automation of two assays for the characterization and selection of potent antibody drug candidates. Both assays rely on HTRF® detection. The first assay quantifies the binding affinity of antibodies to their target antigen, on live cells.
Validation of an Automated Cell-Based Bioluminescent TNFa Blocker Bioassay
BioTek Instruments
TNFa blocker biopharmaceuticals represent an important and successful class of protein drugs used in the treatment of several autoimmune diseases. Bioassays are indispensible tools in biopharmaceutical drug development and commercialization that are used to quantify biological activity and stability of drugs or drug candidates. The automation of these assays can serve to create an accurate, robust process which can allow the researcher to perform other more important functions.
Improving Cell-Mediated Cytotoxicity Assessment through the Use of an Automated Luminescent ADCC Assay
BioTek Instruments
Assays that can assess the ability of a biosimilar to act in a manner similar to the original biologic have seen increased interest. This poster describes the use of a non-radioactive luminescent chemistry to simplify the assay process and provide improved data quality.
Antigen Determination in Autoimmune Hepatitis Type1
Institute of Liver and Biliary Sciences
Objectives of this project were to exploit the database in indian setting to determine nuclear antigens as target for antinuclear antibodies (ANA) in patients of autoimmune hapatitis (AIH) type1.
Biopharmaceuticals Hiding in the Woods
University of New Brunswick
Suggestions are provided of how efficient industrial bioprocessing can be accomplished, independently of highly expensive molecular biology approaches, in order to recover natural products of medicinal value from wild plant species.
Expansion of mesenchymal stem cells from frozen UCB
StemCare A/S and Bioneer A/S
Umbilical cord blood (UCB) has recently been the focus of clinical applications. UCB contains of hematopoietic stem cells and mesenchymal stem cells (MSC). Clinical studies shows that MSC can be used in regenerative medicine hereby treatment of cardiac diseases. The aim of this project is to establish a protocol for isolation of MSCs from frozen UCB. This study demonstrated that it’s possible to expand MSC.
A Mix-and-Read Cell-Based Assay for Antibody Screening Against Epidermal Growth Factor Receptor
TTP Labtech Ltd
The conventional antibody screening assay based on antibody-antigen binding has been enzyme-linked immunosorbent assay (ELISA). While tedious and consuming, ELISA has proved sufficient for the identification of antibodies directed against secreted antigens. However, cell surface antigens (e.g. GPCRs) provide challenges for ELISA due to the shortage of soluble antigens and high variability resulting from loss of cells during wash procedures.
Facing the challenges in bio-pharmaceutical production: newly developed polymer-based ion exchange chromatography media and their application to the purification for Immunoglobulin – from egg yolk
YMC
Much attention has been given to ion exchange (IEX) media as a means to improve productivity as a result of increasing demand for higher efficiency on the downstream process. Until recently, strain optimisation for high productivity and upstream purification were the bottlenecks for most bio-processes.
Development and NDA-Level Validation of a Real-Time PCR Procedure for Detection and Quantification of Residual E.coli DNA Contamination of Biopharmaceutical Products
Aptuit, Inc.
Escherichia coli (E. coli) has been commonly used for the production of biopharmaceuticals. Among the impurities that must be monitored in biopharmaceuticals is residual host-cell DNA (HCD). This study describes the development and subsequent NDA-level validation of a real time PCR procedure developed in response to a client’s need to improve the sensitivity of detection and quantification of residual E. coli HCD in their drug product.
Gene Expression Profiling of Archived FFPE Samples
Miltenyi Biotech
According to the BBMRI (Biobanking and Biomolecular Resources Research Infrastructure) about 8,000,000 formalin-fixed paraffin-embedded (FFPE) samples derived from a multitude of different diseases have been collected in medical centers and biobanks all over Europe during the last decades.
Contaminant bovine IgG assay
Molecular Devices
Fetal calf serum containing bovine IgG is commonly used in mammalian cell culture media for the production of recombinant pharmaceuticals. During the purification process of a recombinant pharmaceutical, bovine IgG may be copurified with the product, and may represent a biological hazard for clinical use. Therefore, it may be necessary to assay for contaminant bovine IgG in a final product originating from mammalian cells.
LanthaScreen TR-FRET Assay Performance with Thermo Scientific Varioskan Flash Spectral Scanning Multimode Reader
Thermo Fisher Scientific
LanthaScreen technology uses time-resolved fluorescence resonance energy transfer (TR-FRET) to study multiple target classes including protein kinases, nuclear hormone receptors, as well as proteases and ubiquitinated proteins.
Sample Reformatting and Sample Archiving
FluidX
Biobanking is becoming a central element in the study of patient genetic data and clinical application of genetic research. Until recently, collections of DNA samples have tended to be fairly small and localized with varied sample containers that were unsuitable for an increasing throughput and automated system use.
Reading Racked 2D-Coded Cryo Tubes directly from -80ºC Freezer
FluidX
With the storage of biological samples such as DNA, protein, blood fractions and viable cells becoming commonplace. The need to store them at lower temperatures has resulted in reading challenges for traditional rack readers.
Integrated Solutions for High-Throughput Bioprocessing Applications
Thermo Fisher Scientific
Advances in blood banking, industrial biotechnology, bio-production and pharmaceutical laboratories have driven the need to process multiple sample batches.
Molecular Devices
Fetal calf serum containing bovine IgG is commonly used in mammalian cell culture media for the production of recombinant pharmaceuticals. During the purification process of a recombinant pharmaceutical, bovine IgG may be copurified with the product, and may represent a biological hazard for clinical use. Therefore, it may be necessary to assay for contaminant bovine IgG in a final product originating from mammalian cells.
LanthaScreen TR-FRET Assay Performance with Thermo Scientific Varioskan Flash Spectral Scanning Multimode Reader
Thermo Fisher Scientific
LanthaScreen technology uses time-resolved fluorescence resonance energy transfer (TR-FRET) to study multiple target classes including protein kinases, nuclear hormone receptors, as well as proteases and ubiquitinated proteins.
Sample Reformatting and Sample Archiving
FluidX
Biobanking is becoming a central element in the study of patient genetic data and clinical application of genetic research. Until recently, collections of DNA samples have tended to be fairly small and localized with varied sample containers that were unsuitable for an increasing throughput and automated system use.
Reading Racked 2D-Coded Cryo Tubes directly from -80ºC Freezer
FluidX
With the storage of biological samples such as DNA, protein, blood fractions and viable cells becoming commonplace. The need to store them at lower temperatures has resulted in reading challenges for traditional rack readers.
Integrated Solutions for High-Throughput Bioprocessing Applications
Thermo Fisher Scientific
Advances in blood banking, industrial biotechnology, bio-production and pharmaceutical laboratories have driven the need to process multiple sample batches.
©2012 Technology Networks, all rights reserved.